Table 4 Clinical trials evaluating the anti-metastatic inhibition of invadopodia-targeted drugs
From: Invadopodia in cancer metastasis: dynamics, regulation, and targeted therapies
Drug | Gene | Cancer type | Interference | Clinical trial (NCT number) |
|---|---|---|---|---|
Aflibercept | EGFR ERBB2 ERBB3 ERBB4 | Colorectal Cancer | Aflibercept + Oxaliplatin +  5-Fu + Folinic acid Aflibercept + Folfiri | NCT00851084 NCT00561470 |
Prostatic Cancer | Aflibercept + Docetaxel +  Prednisone or Prednisolone | NCT00519285 | ||
Bevacizumab | VEGFA | Breast Cancer | Abraxane + Bevacizumab Carboplatin + Bevacizumab +  Herceptin | NCT00281528 NCT01004172 |
Colorectal Cancer | Pembrolizumab +  Bevacizumab + Binimetinib 5-Fluorouracil + Bevacizumab + Leucovorin + Oxaliplatin | NCT03475004 NCT00508872 | ||
Esophagogastric Adenocarcinomas | Capecitabine + Oxaliplatin + Bevacizumab | NCT00447330 | ||
Cabozantinib | MET | Prostate cancer | Cabozantinib | NCT01834651 |
Non small cell lung cancer | Cabozantinib | NCT02132598 | ||
Cetuximab | EGFR | Colorectal Cancer | Cetuximab Cetuximab + Oxaliplatin Cetuximab + Oxaliplatin +  Capecitabine | NCT00083720 NCT00125034 NCT00444678 |
Dasatinib | ABL2 PDGFRBSRC | Breast cancer | Dasatinib Dasatinib + Zoledronic acid | NCT00371254, NCT00410813 NCT00566618 |
Head and neck cancer | Dasatinib | NCT00507767 | ||
Erlotinib | EGFR ERBB2 | Non small cell lung cancer | Erlotinib + Romidepsin | NCT01302808 |
Esophageal Cancer | Erlotinib + 5-Fluorouracil + Leucovorin + Oxaliplatin | NCT00539617 | ||
Everolimus | MTOR | Breast Cancer | Letrozole + Lapatinib + Everolimus Everolimus + Vinorelbine + Trastuzumab | NCT01499160 NCT01305941 |
Sirolimus | MTOR | Prostate Cancer | Carboplatin + Docetaxel + Sirolimus | NCT02565901 |
Sorafenib | BRAF PDGFRB | Advanced or Metastatic Urothelial Cancer | Sorafenib Tosylate | NCT00112671 |
Colorectal Cancer | Sorafenib + Mfolfox6 | NCT00865709 | ||
Sunitinib | PDGFRB | Melanoma | Sunitinib Malate | NCT00462982 |
Adenocarcinoma of the Gastroesophageal Junction | Sunitinib Malate + Capecitabine | NCT00891878 |